Nexavar (sorafenib tosylate) — United Healthcare
myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement
Initial criteria
- Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Nexavar therapy
Approval duration
12 months